Product image of Hylvastam (Sodium Hydrogen Carbonate) supplied by GNH India

Hylvastam

Active Ingredient:
Sodium Hydrogen Carbonate
Origin:
EU

Hylvastam (Sodium Hydrogen Carbonate)

Sodium Hydrogen Carbonate, the active ingredient in Hylvastam, is a buffering agent presented as an injectable solution for intravenous use. It helps correct acid‑base disturbances and is employed in clinical settings to manage metabolic acidosis, cardiac arrest, and certain drug toxicities. The compound works by increasing plasma bicarbonate concentration, thereby raising blood pH and supporting cardiovascular stability.

GNH India supplies Hylvastam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Macure Pharma Aps

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Hylvastam is used intravenously to address conditions involving acid‑base imbalance and cardiac emergencies.

  • Metabolic Acidosis: restores normal pH by supplying bicarbonate ions.
  • Cardiac Arrest: improves myocardial contractility and vascular tone during resuscitation.
  • Hyperkalemia: facilitates intracellular shift of potassium as part of emergency management.
  • Drug Overdose (e.g., tricyclic antidepressants): mitigates toxicity by alkalinizing plasma and urine.

How It Works

  • Sodium Hydrogen Carbonate acts as a systemic buffer; when administered intravenously it dissociates to sodium and bicarbonate ions. The bicarbonate combines with hydrogen ions to form carbonic acid, which is rapidly converted to CO2 and water, thereby reducing acidity and raising blood pH. This shift supports enzymatic function, stabilizes cardiac electrophysiology, and promotes the redistribution of certain electrolytes.

Side Effects

Intravenous sodium bicarbonate may cause a range of adverse reactions.

Common Side Effects

  • Hypernatremia: elevated serum sodium levels.
  • Metabolic Alkalosis: excessive rise in blood pH.
  • Fluid Overload: risk of volume expansion.
  • Hypokalemia: lowered serum potassium.
  • Increased CO2 Production: may exacerbate respiratory compromise.
  • Local Infusion Site Irritation: pain or phlebitis at the catheter site.

Serious or Rare Side Effects

  • Severe Alkalosis: can lead to neuromuscular irritability or seizures.
  • Pulmonary Edema: especially in patients with heart failure.
  • Cardiac Arrhythmias: due to electrolyte shifts.
  • Paradoxical Intracellular Acidosis: in specific metabolic conditions.
  • Severe Hypernatremia: may cause neurologic dysfunction.
  • Anaphylactoid Reactions: rare hypersensitivity to the solution.

Precautions & Warnings

When using Hylvastam, clinicians should observe several safety measures.

  • Renal Function: monitor closely in patients with impaired kidney function.
  • Cardiac Status: assess before administration in heart failure or arrhythmia risk.
  • Electrolyte Balance: check serum sodium and potassium levels prior to and during therapy.
  • Acid‑Base Status: avoid in patients already alkalotic.
  • Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
  • Store at ambient temperature: keep in the original container, protect from light and moisture.

Avoid Interactions

Sodium Hydrogen Carbonate can affect the pharmacokinetics of several medications.

Major Interactions (Avoid)

  • Acid‑dependent antibiotics (e.g., penicillins, tetracyclines): reduced absorption and efficacy.
  • Lithium: increased serum lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely)

  • Antihypertensives (e.g., ACE inhibitors): may enhance hypotensive effects.
  • Digoxin: altered serum levels due to changes in electrolyte balance.
  • NSAIDs: potential for increased sodium and water retention.
  • Warfarin: possible alteration of INR values requiring closer monitoring.

Frequently Asked Questions

Hylvastam is an intravenous formulation of sodium hydrogen carbonate used to correct metabolic acidosis, support resuscitation during cardiac arrest, manage hyperkalemia, and mitigate certain drug overdoses by alkalinizing the blood and urine.

Sodium hydrogen carbonate dissociates into sodium and bicarbonate ions after infusion. The bicarbonate binds excess hydrogen ions, forming carbonic acid, which is quickly converted to carbon dioxide and water, thereby raising blood pH and restoring acid‑base balance.

The appropriate dose of Hylvastam is determined by the prescribing clinician based on the patient’s clinical condition, laboratory values, and response to therapy. Dosage regimens are individualized and should follow institutional protocols.

Safety data for sodium hydrogen carbonate in pregnancy and lactation are limited. It should only be used when the potential maternal benefit outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Hylvastam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Hylvastam provides rapid intravenous delivery of bicarbonate, offering faster correction of severe acidosis compared with oral agents. Unlike some oral buffers, it allows precise titration in acute settings, but it requires careful monitoring of electrolytes and acid‑base status.

Hylvastam should be stored at ambient temperature, protected from light and moisture, and kept in its original sealed container. Do not freeze the solution, and inspect for particulate matter before administration.

Hylvastam is administered intravenously, typically via a controlled infusion. The rate and volume are adjusted according to the patient’s acid‑base status, electrolyte levels, and clinical response, following established medical guidelines.

Serious risks include severe metabolic alkalosis, hypernatremia, pulmonary edema, cardiac arrhythmias, and paradoxical intracellular acidosis. Prompt recognition and correction of these complications are essential during therapy.

Patients with known hypersensitivity to sodium bicarbonate, uncontrolled alkalosis, severe renal impairment without monitoring, or those for whom the risks outweigh benefits—such as certain pregnant individuals—should not receive Hylvastam unless specifically directed by a qualified clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.